Back to Search Start Over

Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.

Authors :
Pan C
Ng K
Voutsinas J
Barber B
Rizvi ZH
Marchiano E
Ferrandino RM
Futran N
Laramore GE
Liao JJ
Parvathaneni U
Panjwani N
Martins RG
Rodriguez CP
Wu QV
Source :
BMC cancer [BMC Cancer] 2024 Nov 15; Vol. 24 (1), pp. 1406. Date of Electronic Publication: 2024 Nov 15.
Publication Year :
2024

Abstract

Background: We previously reported in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs), pretreatment higher lactate dehydrogenase (LDH) and absolute (abx) neutrophils as well as lower percent (%) lymphocytes correlated with worse overall survival (OS). In this study we aimed to develop a prognostic signature for HNSCC treated with ICIs using these peripheral blood biomarkers (PBBMs).<br />Methods: Adults with R/M HNSCC treated with ICIs at our institution from 08/2012 to 03/2021 with pretreatment PBBMs were included. Follow-up continued until 02/15/2022. The cohort (n = 151) was randomly split into training (n = 100) and testing (n = 51) datasets. A prognostic score incorporating LDH, % lymphocytes, and abx neutrophils was developed from the training dataset using Cox proportional hazards regression. In the training dataset, a grid search identified the optimal cutpoints classifying patients into high, medium, and low-risk groups (trichotomized signature) as well as high vs. low-risk groups (dichotomized signature). The prognostic score, dichotomized and trichotomized signatures were then validated in the testing dataset.<br />Results: Training and testing datasets showed no clinically meaningful differences in clinicodemographic characteristics or PBBMs. An OS prognostic model was developed from the training dataset: Risk score = 1.24*log10(LDH) - 1.95*log10(% lymphocytes) + 0.47*log10(abx neutrophils). Optimal risk score cutpoints for the dichotomized and trichotomized signatures were defined in the training dataset, and Kaplan-Meier curves for both dichotomized and trichotomized signatures showed good separation between risk groups. Risk scores were calculated in the testing dataset, where the trichotomized signature demonstrated overlap between low and medium-risk groups but good separation from the high-risk group while the dichotomized signature showed clear separation between low and high-risk groups. Higher risk score correlated with worse OS (HR 2.08, [95%CI 1.17-3.68], p = 0.012). Progression-free survival Kaplan-Meier curves likewise showed excellent separation between dichotomized risk groups in the training and testing datasets.<br />Conclusions: We developed a prognostic signature for OS based on 3 previously identified PBBMs for HNSCC treated with ICIs and identified a high-risk group of patients least likely to have survival benefit from ICIs. This signature may improve ICI patient selection and warrants validation in an independent cohort as well as correlation with CPS.<br />Competing Interests: Declarations Ethics approval and consent to participate This study was reviewed and approved by the Fred Hutchinson Cancer Research Institutional Review Board (IRB ID: STUDY00007717). The requirement to obtain informed consent was waived. Consent for publication Not applicable. Competing interests Conflict of Interest Disclosures: Dr. Futran reported educational consultancy role for Stryker Corporation. Dr. Rodriguez reported receipt of institutional research funding from AstraZeneca, Ayala, Bristol Myers Squibb, Ignyta, and Merck, and reported advisory board membership for Cue Biopharma. The other authors declare no potential conflicts of interest.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1471-2407
Volume :
24
Issue :
1
Database :
MEDLINE
Journal :
BMC cancer
Publication Type :
Academic Journal
Accession number :
39543541
Full Text :
https://doi.org/10.1186/s12885-024-13051-6